Based on the US Food and Drug Administration-cleared cut-off point for HF risk stratification (≤17.8 ng/mL low risk, 17.9–25.9 ng/mL intermediate risk, >25.9 ng/mL high risk), a threshold for plasma Gal-3 of 17.8 ng/mL was applied. Here, LGALS3 is linked to hydrops fetalis.